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Abstract
Introduction Human models of noninvasive breast tumors are
limited, and the existing in vivo models do not mimic inter- and
intratumoral heterogeneity. Ductal carcinoma in situ (DCIS) is
the most common type (80%) of noninvasive breast lesions. The
aim of this study was to develop an in vivo model whereby the
natural progression of human DCIS might be reproduced and
studied. To accomplish this goal, the intraductal human-in-
mouse (HIM) transplantation model was developed. The
resulting models, which mimicked some of the diversity of
human noninvasive breast cancers in vivo, were used to show
whether subtypes of human DCIS might contain distinct
subpopulations of tumor-initiating cells.
Methods The intraductal models were established by injection
of human DCIS cell lines (MCF10DCIS.COM and SUM-225),
as well as cells derived from a primary human DCIS (FSK-H7),
directly into the primary mouse mammary ducts via  cleaved
nipple. Six to eight weeks after injections, whole-mount,
hematoxylin and eosin, and immunofluorescence staining were
performed to evaluate the type and extent of growth of the
DCIS-like lesions. To identify tumor-initiating cells, putative
human breast stem/progenitor subpopulations were sorted from
MCF10DCIS.COM and SUM-225 with flow cytometry, and their
in vivo growth fractions were compared with the Fisher's Exact
test.
Results Human DCIS cells initially grew within the mammary
ducts, followed by progression to invasion in some cases into
the stroma. The lesions were histologically almost identical to
those of clinical human DCIS. This method was successful for
growing DCIS cell lines (MCF10DCIS.COM and SUM-225) as
well as a primary human DCIS (FSK-H7). MCF10DCIS.COM
represented a basal-like DCIS model, whereas SUM-225 and
FSK-H7 cells were models for HER-2+  DCIS. With this
approach, we showed that various subtypes of human DCIS
appeared to contain distinct subpopulations of tumor-initiating
cells.
Conclusions The intraductal HIM transplantation model
provides an invaluable tool that mimics human breast
heterogeneity at the noninvasive stages and allows the study of
the distinct molecular and cellular mechanisms of breast cancer
progression.
Introduction
More than 182,000 women were diagnosed with breast can-
cer, and more than 40,000 died of their disease in 2008 in the
United States alone [1]. The 5-year survival rates for noninva-
sive and locally invasive breast cancers are 98% and 83.3%,
respectively. However, the 5-year survival rate is significantly
DCIS: ductal carcinoma in situ; DCIS.COM: MCF10DCIS.COM cell line; H&E: hematoxylin and eosin staining; HIM: human in mouse.Breast Cancer Research    Vol 11 No 5    Behbod et al.
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reduced to 27.1% for cancers that have spread to distant sites
[1]. Therefore, more research is needed on early detection and
prevention, and progress in this field requires a better under-
standing of the heterogeneity of early breast cancer lesions.
Individualized preventive strategies may be the key for effec-
tive prevention and ultimately for improved patient survival.
Most DCIS lesions in mice originate from the terminal
branches of the mammary tree. This also is true in humans,
where the majority of DCIS originate in the terminal duct lobu-
lar units (TDLUs). The origin of lobular carcinoma in situ (LCIS)
is less clear, but most investigators favor the idea that LCIS
also originates in the TDLUs. Microarray and histologic studies
indicate that the heterogeneity in human breast cancers arises
early at the noninvasive stages in DCIS [2]. The mechanisms
for invasive progression may be more complex than is
reflected in the current histologic and genetic studies. Thus, it
becomes important to develop in vivo models of human DCIS
to investigate the mechanisms involved in the generation of
inter- and intralesion heterogeneity. The degree of heterogene-
ity may explain differences in patient outcome with respect to
a risk for malignant progression.
Human breast noninvasive models are limited. Furthermore,
the existing models do not mimic the heterogeneity of human
disease. To date, two cell-line models are used for the study of
noninvasive breast cancers, SUM-225 and DCIS.COM [3].
DCIS.COM was derived from cell culture of a lesion formed by
xenotransplantation of MCF10AT cells. Subcutaneous injec-
tion of DCIS.COM into nude mice results in rapidly growing
lesions that are predominantly comedo (a more-aggressive
type of DCIS with central necrosis) [4]. The DCIS lesions
appear in about 3 weeks and are composed of luminal epithe-
lial cells surrounded by both a myoepithelial cell layer and a
basement membrane. Some areas of early lesions will
progress to invasive cancer in about 5 to 6 weeks [5]. SUM-
225 was isolated from a chest-wall recurrence of a human
DCIS. Similar to those of DCIS.COM, xenografts of the SUM-
225 cell line result in the formation of DCIS-like tumors in
about 2 weeks. Human DCIS tissue fragments also have been
implanted subcutaneously in nude mice with a take rate of
about 66% [6].
The aim of the current study was to develop models that would
better represent the distinct subtypes of DCIS. We used an
intraductal-transplantation model. This method has been used
for the delivery of hormones, cytokines, and growth factors to
goats, cows, and rats [7]. However, to our knowledge, no pre-
viously published literature exists on the use of this method for
the purpose of growth and expansion of any breast cancer cell
lines or primary cancer cells or for studying the mechanisms of
breast cancer invasion. The unique feature of this approach is
that the cancer cells are introduced directly into the primary
mammary ducts of immunocompromised mice, thus mimicking
DCIS in its normal environment. Furthermore, the model allows
us to follow the natural progression of human breast cancers
(i.e., their initial growth as carcinoma in situ inside the ducts,
sometimes followed by invasion into the stroma by overcoming
the barriers of an intact myoepithelial cell layer and a basement
membrane. We developed two stable subtype-specific
xenograft models, representing a basal subtype and a Her-2-
overexpressing subtype. These xenograft lines were devel-
oped by using the previously described DCIS-derived cell
lines, MCF10-DCIS.COM (here referred to as DCIS.COM)
and SUM-225. Additionally, a xenograft line was developed
from a human primary DCIS (FSK-H7). Our ultimate goal is to
develop multiple models of human primary DCIS to mimic the
heterogeneity of human noninvasive breast lesions. Such mod-
els should facilitate the design of therapeutic strategies for
prevention based on a better understanding of distinct mech-
anisms of the malignant progression of breast cancer.
Materials and methods
Intraductal transplantation method
Recipients are 6- to 10-week-old virgin female SCID-beige
mice. Before transplantation, cells are resuspended as single
cells in PBS and counted from DCIS.COM, SUM225, or pri-
mary human DCIS cells. A 30-gauge Hamilton syringe, 50-μl
capacity, with a blunt-ended 1/2-inch needle is used to deliver
the cells. The mice are anesthetized, and a Y-incision is made
on the abdomen to allow the skin covering the inguinal mam-
mary fat pads to be peeled back to expose the inguinal gland.
The nipple of the inguinal gland is snipped so that the needle
can be directly inserted through the nipple. Two microliters of
cell-culture medium (with 0.1% trypan blue) containing cells at
a concentration of 2,500 to 5,000 cells/μl are injected; the
injected liquid can be visually detected in the duct. The skin
flaps are repositioned normally and held together with wound
clips. The primary human DCIS was chopped very finely by
using a Teflon block and razor blade or scalpel followed by
overnight enzymatic digestion in DMEM/F12 with antibiotics,
supplemented with collagenase (1.0 mg/ml) and hyaluroni-
dase (100 U/ml).
Animal and human experiments were conducted by following
protocols approved by the Baylor College of Medicine Animal
Care and Use and Human Subjects Committee. An informed
consent was deemed not to be required by the Human Sub-
jects Committee. [See Additional data file 1 for a video dem-
onstration of the intraductal method.]
Cell lines
MCF10DCIS.COM and SUM-225 were purchased from
Asterand, Inc. (Detroit, MI) and were maintained according to
the supplier's guidelines.
Histologic procedures
Whole mount and H&E were performed as described previ-
ously [8].Available online http://breast-cancer-research.com/content/11/5/R66
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Immunofluorescence and reagents
Immunofluorescence (IF) was performed after tissue deparaffi-
nization by clearance in xylene and hydration through graded
ethanol series. Microwave antigen retrieval (20 min) in 10 m M
sodium citrate was performed for all the antibodies used for IF.
A 5% solution of bovine serum albumin in phosphate-buffered
saline + 0.5% Tween 20 was used as blocking buffer. Sec-
tions were incubated with the following primary antibodies
overnight at 4°C: ERα rabbit polyclonal 1:50 (Novocastra;
6F11, NCL-ER-6F11, Newcastle Upon Tyne, Tyne and Wear,
UK), anti-human SMA 1:100 (1A4-Dako, M0851, Dako, Glos-
trup, Denmark), anti-mouse SMA 1:200 (A14; Sigma, A2547,
St. Louis, MO, USA), CK5 1:50 (XM26, Vector, VP-C400,
Burlingame, California, USA), CK8 1:50 (C51, Zymed, 18-
0185, San Francisco, California, USA), Her-2 1:50 (SP3, Lab-
vision, RM-9103-SO, Fermont, California, USA), Cytokeratin
(AE1/3)1:50 (AE1/AE3, Dako, M3515, Glostrup, Denmark),
CK-19 1:50 (Clone A53-B, Lab Vision, MS-198-P0, Fremont,
California, USA), and Her-1 1:50 (Clone 31G7, Zymed Labo-
ratories, San Francisco, California, USA). Nuclei were counter-
stained with 4',6-diamidino-2-phenylindole (DAPI; Vector
Laboratories, Burlingame, California, USA) and TO-PRO-3
iodide (Invitrogen, T3605, Carlsband, California, USA). Sec-
ondary antibodies included anti-mouse Alexa 488 and anti-
rabbit Alexa 594 (Molecular Probes, Carlsband, California,
USA). Confocal microscopy was performed by using a laser-
scanning confocal microscope (model 510; Carl Zeiss Micro-
Imaging, Inc., Thornwood, NY, USA). The acquisition software
used was LSM image browser (Carl Zeiss MicroImaging, Inc.,
Thornwood, NY, USA). Phase-contrast images were captured
w i t h  a n  i n v e r t e d  m i c r o s c o p e  ( C K 4 0 - S L P ;  O l y m p u s ) .  T h e
acquisition software used was Photoshop 5.0 (Adobe). [See
Additional data file 2 for detailed information on primary
antibodies.]
Flow cytometry
Primary antibodies used were anti-human MUC-1 1:250
(Stem Cell Technologies, 01423, Vancouver, BC, Canada),
CD10-APC 1:10 (BD Bioscience, 340923, San Jose, Califor-
nia, USA), EPCAM-FITC (Stem Cell Technologies, 10109,
Vancouver, BC, Canada), Biotinylated AC133 1:5 (Miltenyi
Biotec, 130-090-664, Bergisch Gladbach, Germany), PE-
CY5-conjugated rat anti-human CD49f 1:50 (BD Pharmingen,
551129, San Diego, California, USA), PE-conjugated mouse
anti-human CD44 1:50 (BD Pharmingen, 555479, San Diego,
California, USA), PE-conjugated mouse anti-human CD29
1:50 (BD Pharmingen, 556049, San Diego, California, USA),
FITC-conjugated mouse anti-human CD24 1:50 (BD Pharmin-
gen, 555427, San Diego, California, USA), and Biotinylated
Thy-1 (Abcam, ab1154, Cambridge, MA, USA). Biotinylated
antibodies were labeled by using Streptavidin-PE-CY5 (Invit-
rogen, SA1012, Carlsband, California, USA). MUC-1 antibody
was conjugated by using FITC anti-mouse Igg1 (Biolegend,
406605, San Diego, California, USA). Isotype controls used
were FITC mouse Igg1 (Biolegend, 400107, San Diego, Cali-
fornia, USA), FITC mouse Igg2a (400207, Biolegend, San
Diego, California, USA), PE mouse Igg2b (Biolegend,
401207, San Diego, California, USA), PE-CY5 mouse Igg1
(BD Bioscience, 550618, San Jose, California, USA), and PE-
CY5 Rat Igg2a (Biolegend, 400509, San Diego, California,
USA). Cells were stained at a cell concentration of 1 × 107/ml
for 30 min on ice followed by washes in Hanks' Balanced Salt
Solution containing 2% fetal bovine serum (HBSS; Gibco
BRL, Carlsband, California, USA). Flow-cytometry analysis
and acquisition were performed by using the BD LSR II flow
cytometer and BD FACSDIVA based software (BD Bio-
sciences, San Jose, California, USA). Flow-cytometry sorting
was performed by using FACSAria (BD Biosciences, San
Jose, California, USA). The fluorescence expression level is
arbitrarily designated as low (lo) if the log10 of median fluores-
cence intensity (FI) is between about 0 to 2, medium (med), if
the FI is between about 2.1 and 3.6, and high (hi) if the FI is
higher than about 3.7.
Immuno-FISH
Immuno-FISH was performed as previously described in [5].
Results
Intraductal transplantation as a model for human DCIS
A limiting factor for studying human DCIS is the lack of suita-
ble in vivo models. Furthermore, sufficient amounts of primary
DCIS tissue available for research purposes are often inade-
quate. Therefore, the main goals were to design a method for
expansion of human DCIS tissue in vivo and to develop mod-
els that would represent various subtypes of human DCIS.
Many investigators have tried, with limited success, to develop
xenograft models of human DCIS by a variety of methods
including humanized fat-pad transplantation. The reason for
the limited success may be that DCIS has been treated like an
invasive lesion rather than a lesion limited in its growth poten-
tial under very restrictive conditions. With the idea that DCIS
initiates and grows inside the ducts, we used intraductal trans-
plantation. This approach involves injection of human DCIS
cells directly into the primary ducts (Figure 1, and video [see
Additional data file 1] demonstrate the intraductal-transplanta-
tion technique). We intentionally mimicked DCIS in the mouse
to the closest condition to that found in vivo in the human dis-
ease. Two established DCIS cell lines, DCIS.COM, SUM-225,
and a primary human DCIS lesion were used. The primary
human DCIS cells were obtained by digestion of a primary
human DCIS tumor. A pathologist diagnosed the primary
human DCIS lesion. The researchers were blind to any other
patient identifiers. The take rate was 90% for all three cell
lines. The cells were injected at 40,000 cells in 2 μl. Three rep-
licates for DCIS.COM (ratio of growth, 9:10, 5:6, and 6:6),
two replicates for SUM-225 (ratio of growth, 5:6 and 5:6), and
one replicate for the primary human DCIS, FSK-H7 (ratio of
growth, 9:10) were found. None of the xenografts in this study
was serially transplanted. Both DCIS.COM and SUM-225 are
unique because they progress through a DCIS-like stageBreast Cancer Research    Vol 11 No 5    Behbod et al.
Page 4 of 11
(page number not for citation purposes)
during tumor formation. The DCIS-like lesions generated by
the DCIS.COM cell line slowly progressed to invasive lesions
in 10 weeks, whereas those generated by the SUM-225 did
not become invasive during the 10-week study period. In one
study, three (25%) of 10 mammary fat pads injected with
DCIS.COM generated invasive cancers in 10 weeks. This is in
contrast to other established invasive breast cancer cell lines,
such as MCF-7, that develop extensive invasive cancers in as
early as 4 weeks after intraductal injections in six of six fat pads
(unpublished data). None of the DCIS-like lesions generated
by FSK-H7 (primary human DCIS cells) showed invasion dur-
ing the 6-week study period.
Figure 2 shows whole-mount and hematoxylin and eosin (H&E)
stains of intraductal lesions generated from DCIS.COM (A, B),
SUM-225 (C, D), and the primary human DCIS, FSK-H7 (E, F)
6 weeks after injection. SUM-225 exhibited a comedo pattern,
whereas DCIS.COM exhibited a cribriform pattern. Previously,
it was reported that DCIS.COM generates a comedo DCIS
when injected subcutaneously [3]. This difference, most likely,
is due to the subcutaneous versus intraductal sites of injec-
tions. Injection of the primary human DCIS cells (FSK-H7) gen-
erated apocrine-like DCIS lesions. Interestingly, the whole
mounts show that many of the growths appear to be at the
periphery and separated from the point of injection. This may
be because the cells were injected when the SCID-beige mice
were 6 to 8 weeks old, when the ducts are expanding. At the
time of ductal expansion, the terminal ducts may provide a
favorable environment for cancer cell growth. The reason for
this effect is not known.
To assess the human and mouse origin of cells within the intra-
ductal lesions, immuno-fish (FISH) was performed by using
anti-mouse smooth muscle actin (SMA) (Figure 3A-C) and
anti-human pan-cytokeratin antibodies (D-E), fluorescently
labeled human (green) (F-J), and mouse (red) Cot1 DNA
probes for FISH (K-O). The data show that human cells, indi-
cated by green human Cot1 probe staining, are surrounded by
mouse myoepithelial cells and myofibroblasts, indicated by a
red mouse Cot1 probe. Therefore, the intraductal model reca-
pitulates human DCIS by allowing the cancer cells to grow
within the boundaries of the mouse basement membrane and
myoepithelial cells. Furthermore, the model provides a unique
opportunity for studying the factors that influence the process
of cancer cell invasion into the stroma.
The transitional process of in situ breast lesion to invasive car-
cinoma is currently poorly understood. It has been proposed
that the loss of myoepithelial cells concurrent with degradation
of the basement membrane may play a major role in DCIS inva-
sive progression. A recent report described the role of myoep-
ithelial cells in this process in detail [5]. By subcutaneous
transplantation of DCIS.COM, this group demonstrated that
myoepithelial cells suppress, whereas fibroblasts enhance
DCIS invasive progression. It was further demonstrated that
the loss of myoepithelial expression of TGFβ R2 and SMAD-4,
Gli-2, and MMP14 play a role in the invasive progression of
DCIS [5]. Thus, the current model allows the study of many
early processes of breast cancer cell invasion into the stroma,
including the interactions of cancer cells with the surrounding
normal luminal and myoepithelial cells as well as the basement
membrane.
Developing subtype-specific models of human DCIS 
xenograft lines
The long-term goal of our studies is to develop subtype-spe-
cific stable xenograft models of human DCIS by intraductal
transplantation. The xenograft lines are termed stable if their
morphology, subtype specificity, and invasive properties
remain unchanged with repeated transplantation. Subtype-
Figure 1
Intraductal HIM transplantation model mimics human breast cancer noninvasive-to-invasive progression Intraductal HIM transplantation model mimics human breast cancer noninvasive-to-invasive progression. The model allows temporal analysis of many 
processes involved in early breast cancer invasive progression including intraductal cancer cell growth, the cell interactions with the surrounding 
normal epithelial and myoepithelial cells, and their escape into the surrounding stroma.Available online http://breast-cancer-research.com/content/11/5/R66
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specific xenograft lines should allow one to study the distinct
molecular and biologic mechanisms underlying the invasive
progression of subtypes of human DCIS. We have identified
two cell lines, DCIS.COM and SUM-225, that generate stable
basal-like and Her-2-overexpressing DCIS-like lesions,
respectively. Intraductal xenografts of a human primary DCIS,
FSK-H7, generated Her-2-overexpressing lesions.
Previous studies have shown that immunoassays may be used
to predict the tumor subtypes identified with microarray analy-
ses with a high degree of specificity [see Additional data file
3) [9,10]. Accordingly, immunofluorescence studies using
anti-human cytokeratin-8 (CK-8), CK-19, CK-5, estrogen
receptor (ER), Her-1, and Her-2 antibodies were performed.
Figure 4 shows that SUM-225 and FSK-H7 lesions uniformly
express CK-19 (A, C), whereas DCIS.COM lesions are CK-19
negative (B). SUM-225 and FSK-H7 express Her-2 (D-F),
whereas CK-5 is exclusively expressed by DCIS.COM (G-L).
All three intraductal lesions express CK-8; however, none of
the lesions expresses ER (data not shown). These results sug-
Figure 2
Hematoxylin and eosin (H&E) and whole-mount staining of intraductal xenografts Hematoxylin and eosin (H&E) and whole-mount staining of intraductal xenografts. The panels show whole-mount and H&E staining of xenografts 
generated by intraductal transplantation of DCIS.COM (a, b), SUM-225 (c, d), and FSK-H7 (e, f). The H&E figures depict ×20 magnification, and 
whole mounts were captured at ×1.6 (SUM-225 and DCIS.COM) and ×0.7 (FSK-H7). Cells were injected intraductally (20,000/μl cells in 2 μl of 
PBS) into the primary mammary ducts (via cleaved nipple) of intact 8-week-old immunocompromised SCID-beige female mice. The human primary 
DCIS was enzymatically digested into single cells before injections. The pictures were taken at 6 weeks after injection.Breast Cancer Research    Vol 11 No 5    Behbod et al.
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gest that DCIS.COM generates basal-type lesions, whereas
SUM-225 and FSK-H7 generate Her-2-overexpressing
lesions ([see Additional data file 1], and Figure 4).
DCIS.COM and SUM-225 may contain distinct 
subpopulations with significantly higher in vivo growth 
potential
We further used the intraductal model to test the hypothesis
that xenografts representing two distinct subtypes of DCIS-
like lesions may contain distinct tumor-initiating subpopula-
tions. The two DCIS cell lines were used for this study. The cell
lines were analyzed for the expression of human mammary
basal and luminal surface markers. Figure 5 is a histogram
depicting the relative expression level of the individual markers
in DCIS.COM and SUM-225. The expression level is arbitrarily
designated low (lo) if the log10 of the median fluorescence
intensity (FI) is between about 0 and 2, medium (med) if the FI
is between about 2.1 and 3.6, and high (hi) if the FI is higher
than about 3.7. The data in Figure 5 show that DCIS.COM
expressed a hi level of the basal markers (CD44 and CD49f)
and lo levels of the luminal markers (CD24 and MUC-1). In
contrast, SUM-225 expressed medium levels of the basal
markers and hi levels of the luminal markers. Various subpop-
ulations expressing putative markers of mammary stem and
progenitor cells were sorted with flow cytometry and trans-
planted. These subpopulations (Tables 1 and 2; column 2)
were chosen based on previous reports of markers expressed
by human breast stem/progenitors, mouse mammary epithelial
stem cells, and human breast tumor-initiating cells [10,11].
The gates for the subpopulations sorted and transplanted are
shown in the supplementary data [see Additional data file 4].
Fisher's Exact test was used to compare the in vivo growth
potentials between the various subpopulations. Table 1 shows
transplant results for two replicate experiments per sorted
subpopulation per cell line. DCIS-like lesions are referred to as
in vivo or intraductal growth. The number of fat pads contain-
ing positive intraductal growth over the total number of fat
pads transplanted, growth fractions, and the total number of
ducts containing intraductal growth are listed in Table 1, col-
umns 3, 4, and 5, respectively. [See Additional data file 5.]
Table 2 shows the results of Fisher's Exact test. As depicted
in Table 1 in DCIS.COM, subpopulations expressing high lev-
Figure 3
iFish analysis of a DCIS.COM intraductal xenograft iFish analysis of a DCIS.COM intraductal xenograft. Human-derived DCIS.COM cells are contained within the boundaries of mouse myoepithelial 
cells and basement membrane. The panels depict immunofluorescence staining of paraffin sections from a fat pad containing DCIS.COM intraductal 
lesions by using anti-mouse smooth muscle actin antibody (a-c), anti-human pan cytokeratin antibody (d-e), iFish with fluorescently labeled human 
(green) (f-j), and mouse (red) Cot-1 DNA as probes, and merged images of all panels (p-t).Available online http://breast-cancer-research.com/content/11/5/R66
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els of the basal markers and low levels of the luminal markers
(CD49fhi/CD24lo, CD49fhi/MUC-1lo, and CD44hi/CD24lo)
demonstrated higher in vivo growth fractions and generated
more ducts containing lesions. However, as shown in Table 2
with Fisher's Exact test, none of the subpopulations in
DCIS.COM achieved significantly higher growth fractions
when compared with the random sort. Therefore, the majority
of cells in DCIS.COM possessed tumor-initiating properties.
In contrast, in SUM-225 cells, two subpopulations, CD49fmed/
CD24hi and CD49fmedMUC-1hi, achieved significantly higher
growth fractions compared with the random sort (Table 2).
These subpopulations also generated the largest number of
ducts with lesions (Table 1). Because the tumor-initiating cells
in DCIS.COM and SUM-225 cells expressed distinct surface
markers, we postulate that the tumor-initiating cells may arise
from distinct cell types. However, lineage-tracing experiments
are required to establish whether different types of tumors
arise from distinct cell types. Notably, although tumor forma-
tion was not an end point for this experiment, a few palpable
tumors were found in the random sort as well as the CD44hi/
CD24lo groups in DCIS.COM. None of the SUM-225 subpop-
ulations generated a tumor during the time course of our study
(6 weeks).
Discussion
As an attempt to study the various factors involved in breast
cancer heterogeneity, beginning at the noninvasive stage, we
developed an intraductal xenograft transplantation model. The
model allows one to grow human breast noninvasive lesions
and to follow their progression in vivo. This model offers sev-
eral advantages over current subcutaneous-based models as
well as some disadvantages. This mouse model closely mimics
human DCIS because DCIS initiates inside the ducts, which
provide a natural microenvironment for malignant growth. Fur-
Figure 4
Expression of subtype-specific markers by the intraductally generated DCIS-like lesions Expression of subtype-specific markers by the intraductally generated DCIS-like lesions. Intraductal lesions were generated by injection of SUM-225 
(a, d, g), DCIS.COM (b, e, h), and FSK-H7 (c, f, i). Six weeks after injection, fat pads containing intraductal lesions were removed and fixed, followed 
by paraffin embedding by using standard histological techniques. Paraffin sections were subjected to immunofluorescence studies with antibodies 
against human CK-19 (a-c), Her-2 (d-f), and CK-5 (g-i). Primary antibodies were conjugated to secondary antibodies, Alexa-594 against mouse 
anti-human CK-5 and CK-19 (red), and Alexa-488 against rabbit anti-human Her-2 antibody (green).Breast Cancer Research    Vol 11 No 5    Behbod et al.
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thermore, one can follow the steps involved in cancer cell
growth intraductally, followed by invasion into the stroma. The
interactions of cancer cells with their microenvironment,
including other normal epithelial cells as well as components
of the stroma, may then be studied at the molecular and cellu-
lar levels. Moreover, genetic manipulations of the microenvi-
ronment could potentially be used to study the roles of various
factors involved in cancer cell invasion. One may block the
interactions between cancer cells with their surrounding envi-
ronment to halt or slow an invasive process. Furthermore, the
diversity of the models will present the opportunity to investi-
gate the effects of different chemoprevention agents on a
broad spectrum of human DCIS, thus tailoring treatment to
specific variants of DCIS.
A limitation of this model is that human cancer cells are trans-
planted into immunocompromised mouse mammary ducts,
and thus, the interactions of mouse and human cells may be
artificial. Furthermore, use of an immunocompromised host
may mask the known important effects of some immune cells
in the invasion process. This disadvantage is shared among all
current human models of noninvasive breast cancers.
With the intraductal transplantation model, we tested the
hypothesis that distinct subtypes of DCIS may contain distinct
subpopulations of tumor-initiating cells that possess higher
growth, invasion, and cancer stem cell potential. The distinct
subpopulations enriched in tumor-initiating cells may ultimately
determine a risk for DCIS malignant progression. Surface
markers unique to normal human breast bi-potent and luminal
progenitors, as well as human breast tumor-initiating cells,
were chosen to isolate cells and to assess their in vivo growth
and self-renewal potential. By using the two DCIS cell lines,
our study shows that the subpopulations with higher growth
potential may be distinct. The subpopulation with higher in
vivo  growth potential in the basal DCIS.COM cell line
expressed CD44hi/CD24lo, CD49fhi/CD24lo, and CD49fhi/
MUC-1lo. However, the difference did not achieve significance
when compared with the random sort. This may be because
our sample size was small or the majority of cells in
Figure 5
Flow-cytometry analysis of DCIS.COM and SUM-225 Flow-cytometry analysis of DCIS.COM and SUM-225. Cells grown in 2D were stained by using the indicated anti-human antibodies to the surface 
markers, CD44/CD24, CD49f/CD24, and CD49f/MUC-1. The antibodies were directly conjugated, except for MUC-1, which was conjugated by 
using an anti-mouse FITC antibody. The histograms show expression levels for the indicated surface markers. The expression level is arbitrarily des-
ignated as low (lo) if the log10 of median fluorescence intensity (FI) is between about 0 and 2, medium (med) if the FI is between about 2.1 and 3.6, 
and high (hi) if the FI is higher than about 3.7.Available online http://breast-cancer-research.com/content/11/5/R66
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DCIS.COM possess tumor-initiating properties or both. How-
ever, in the luminal-basal SUM-225 cell line, the CD49fmed/
CD24hi  and CD49fmed/MUC-1hi  subpopulations possessed
higher intraductal growth potential. CD24 and MUC-1 are
both proposed luminal markers. Whether these cells possess
luminal progenitor property will have to be established. The
fact that the majority of cells in DCIS.COM were tumorigenic
may explain why patients who have basal types of breast can-
cers do poorly compared with those with the other types of
human breast cancers. Therefore, different types of tumors
may contain different proportions of tumor-initiating cells or
distinct subpopulations of tumor-initiating cells. Similar studies
in mice show that different mouse mammary tumors may also
contain different proportions of tumor-initiating cells (reviewed
in [11]).
Conclusions
We generated two distinct xenograft models of human breast
noninvasive cancers by intraductal transplantation. This model
offers a novel microenvironment for growth of human noninva-
sive lesions, mimics the diversity of human disease, and is a
suitable tool with which to study the molecular and biologic
mechanisms of breast noninvasive-to-invasive progression.
Additional xenograft lines that represent other tumor subtypes,
Table 1
Transplant results
Cell line Group Number of positive fps/
total
Ratio of positive growth Total number of ducts 
positive
Number of tumors
DCIS.COM Random sort 9/28 32% 22+ 1
DCIS.COM CD49fhi/MUC-1med 4/23 17% 11+
DCIS.COM CD49fhi/MUC-1lo 4/6 67% 9
DCIS.COM CD49fmed/MUC-1lo 4/23 17% 8
DCIS.COM CD49fmed/MUC-1med 4/6 67% 15
DCIS.COM CD49fhi/CD24med 3/8 38% 4
DCIS.COM CD49fhi/CD24lo 5/8 63% 18
DCIS.COM CD44med/CD24med 3/24 13% 3
DCIS.COM CD44med/CD24lo 1/6 17% 1
DCIS.COM CD44hi/CD24lo 7/24 29% 26 3
DCIS.COM CD44hi/CD24med 3/6 50% 5
SUM-225 Random sort 1/16 6% 7+
SUM-225 CD49fmed/MUC-1hi 6/11 55% 31+
SUM-225 CD49fmed/MUC-1med 0/6 0% 0
SUM-225 CD49flo/MUC-1med 1/12 8% 2
SUM-225 CD49flo/MUC-1hi 0/6 0% 0
SUM-225 CD49fmed/CD24hi 4/6 67% 22+
SUM-225 CD49fmed/CD24med 0/6 0% 0
SUM-225 CD44lo/CD24hi 0/6 0% 0
SUM-225 CD44med/CD24med 2/6 33% 8+
A fixed number of cells (DCIS.COM = 5,000 cells in 2 μl and SUM-225 = 10,000 cells in 2 μl) sorted into different subpopulations or randomly 
sorted followed by injection into primary mammary ducts of SCID-beige female mice. Random sort refers to cells sorted based on forward and 
side scatter and irrespective of the expression of specific markers. Six weeks after intraductal injections, glands were removed, subjected to 
whole-mount staining, and the numbers of glands containing positive growth (DCIS-like lesions) were counted. The fraction of growth is referred 
to the number of fat pads containing positive DCIS-like lesions over the total number of fat pads transplanted. The columns contain the following 
data: Column 1 (Cell line): Cell line injected; Column 2 (Group): Subpopulations sorted and injected intraductally; Column 3 (Number of positive 
fps/total): Number of fat pads (fps or glands) containing positive growth (DCIS-like lesions) over the total number of fat pads (glands) 
transplanted; Column 4 (Ratio of positive growth): Fraction of fat pads containing positive growth (DCIS-like lesions); Column 5 (Total number 
ducts positive): Total number of positive ducts (ducts containing DCIS-like lesions) combined in all the positive glands per group (plus sign 
indicates one or more fat pads contained more than seven positive ducts); Column 6 (Number of tumors): Number of palpable tumors formed; 
these data were not included in the statistical evaluation. In DCIS.COM, the expression levels of the basal markers ranged from med to hi, and 
expression levels of luminal markers ranged from lo to med. Therefore, DCIS.COM does not contain CD49flo-, CD44lo-, CD24hi-, or MUC-1hi-
expressing cells. In SUM-225, the expression levels of basal markers CD49f and CD44 ranged from lo to medium, and the expression levels of the 
luminal markers CD24 and MUC-1 ranged from med to hi. Therefore, the groups do not include CD49fhi-, CD44hi-, CD24lo-, and MUC-1lo-
expressing cells.Breast Cancer Research    Vol 11 No 5    Behbod et al.
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such as luminal A and luminal B, must be developed. Further-
more, xenograft lines from various types of primary noninvasive
lesions should be developed. Molecular and cellular character-
ization of the temporal events leading to invasive progression
unique to an individual patient's tumor type may offer new tai-
lored preventive strategies and spare many patients from the
development of invasive and metastatic breast cancers.
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Pair-wise comparison of growth fractions between the various 
subpopulations and the random sort. Fisher's Exact test was used to 
compare the proportions of positive response (lesions in ducts) 
between subpopulations and the random sort (rand) in DCIS.COM 
and SUM-225. A P value < 0.05 indicates a statistically significant 
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